Comparative study on the effect of low intensity laser and growth factors on stem cells used in experimentally-induced liver fibrosis in mice

Naguib, Eman; Kamel, Ahmed; Fekry, Osama; AbdelFattah, Gamal

doi:10.1016/j.ajg.2017.05.012

Cited by 5 publications

(4 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, pretreatment with basic fibroblast growth factor (BFGF) significantly improved the proliferation and differentiation of MSCs in vitro and markedly enhanced the therapeutic effects on liver fibrosis in vivo by enhancing the secretion of HGF in MSCs . Pretreatment with diode laser and HGF on MSCs improved the body and liver weights, reduced vascular congestion, mononuclear cellular infiltration, reduced hepatocyte apoptosis and minimized periportal fibrosis in CCl 4 ‐induced liver fibrosis …”

Section: Pretreatment or Cotreatment Of Mscsmentioning

confidence: 99%

“…53 Pretreatment with diode laser and HGF on MSCs improved the body and liver weights, reduced vascular congestion, mononuclear cellular infiltration, reduced hepatocyte apoptosis and minimized periportal fibrosis in CCl 4 -induced liver fibrosis. 54 Some special medicines which may serve as antioxidative agents and exert anti-inflammatory function in vitro and in vivo, can significantly improve the therapeutic effects of MSCs in eliminating liver fibrosis. Melatonin, which serves as a regulator of circadian rhythms, highly improves the homing ability of MSCs and serves as a promising agent for improving the recovery of liver function in liver fibrosis models.…”

Section: Pretreatment or Cotreatment Of Mscsmentioning

confidence: 99%

See 1 more Smart Citation

Strategies to improve the efficiency of mesenchymal stem cell transplantation for reversal of liver fibrosis

Zhao

Duan

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

End‐stage liver fibrosis frequently progresses to portal vein thrombosis, formation of oesophageal varices, hepatic encephalopathy, ascites, hepatocellular carcinoma and liver failure. Mesenchymal stem cells (MSCs), when transplanted in vivo, migrate into fibrogenic livers and then differentiate into hepatocyte‐like cells or fuse with hepatocytes to protect liver function. Moreover, they can produce various growth factors and cytokines with anti‐inflammatory effects to reverse the fibrotic state of the liver. In addition, only a small number of MSCs migrate to the injured tissue after cell transplantation; consequently, multiple studies have investigated effective strategies to improve the survival rate and activity of MSCs for the treatment of liver fibrosis. In this review, we intend to arrange and analyse the current evidence related to MSC transplantation in liver fibrosis, to summarize the detailed mechanisms of MSC transplantation for the reversal of liver fibrosis and to discuss new strategies for this treatment. Finally, and most importantly, we will identify the current problems with MSC‐based therapies to repair liver fibrosis that must be addressed in order to develop safer and more effective routes for MSC transplantation. In this way, it will soon be possible to significantly improve the therapeutic effects of MSC transplantation for liver regeneration, as well as enhance the quality of life and prolong the survival time of patients with liver fibrosis.

show abstract

Section: Pretreatment or Cotreatment Of Mscsmentioning

confidence: 99%

Section: Pretreatment or Cotreatment Of Mscsmentioning

confidence: 99%

Strategies to improve the efficiency of mesenchymal stem cell transplantation for reversal of liver fibrosis

Zhao

Duan

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…35 One study suggested that different wavelengths had different impact on renal fibrosis; PBM treatments at 532 nm at 3662 mJ/cm 2 decreased the severity of fibrosis, whereas 405 nm (3662 mJ/cm 2 ) and 635 nm (3662 mJ/cm 2 ) had no significant impact. 37 In three other studies, mesenchymal stem cells were treated with PBM therapy leading to a reduction in fibrosis (periportal fibrosis in murine liver); 38 renal fibrosis in murine kidney, and scar formation in a rat's heart with myocardial infarction, respectively. 39 Most of the studies utilized red or near-infrared light (650-804 nm) with either LED or laser sources.…”

mentioning

confidence: 99%

Photobiomodulation Therapy to Mitigate Radiation Fibrosis Syndrome

Tam

Arany

Robijns

et al. 2020

Photobiomodulation, Photomedicine, and Laser Surgery

View full text Add to dashboard Cite

Objective: We evaluated the role of photobiomodulation (PBM) in radiation fibrosis syndrome (RFS). Background: Radiation therapy (RT) is an important treatment utilized in over half of newly diagnosed cancers. Despite its benefits, patients treated with RT may experience acute and chronic significant side effects depending on both treatment-and patient-related factors. RFS is an important long-term side effect of RT, which can adversely impact patient's quality of life and organ function. With improved oncologic outcomes and survival for cancer patients after radiation, there is an unmet need to address long-term side effects of RT, particularly RFS. Results: Photobiomodulation (PBM) using low energy, nonionizing light primarily in the visible (especially red) or near-infrared spectrum has been demonstrated to decrease acute side effects of radiation in rigorously conducted phase III randomized studies; however, its potential benefit in ameliorating chronic radiation side effects, particularly RFS remains to be investigated. Conclusions: This review summarizes the in vitro data, preclinical animal studies and clinical reports, which showcase the potential benefits of PBM treatments in preventing and reversing RFS.

show abstract

“…The effects are generated through the HGF/MET axis [17,18]. Several studies have confirmed that HGF can promote cell proliferation and migration and inhibit apoptosis and tissue fibrosis [19][20][21].…”

Section: Discussionmentioning

confidence: 99%

Characterization and Evaluation of HGF-Loaded PLGA Nanoparticles in a CCl₄-Induced Acute Liver Injury Mouse Model

Lin

Wang

Liu

et al. 2019

Journal of Nanomaterials

View full text Add to dashboard Cite

Liver injury can be caused by various harmful factors since the liver is considered the key organ for detoxifying endogenous and exogenous substances. Hepatocyte growth factor (HGF) can regulate redox homeostasis through the expression of antioxidant proteins when the liver is under injury. However, HGF is easily degraded. In this study, we produced three kinds of HGF-loaded poly(lactic-co-glycolic) acid (PLGA) nanoparticles with an initial addition of 2 μg HGF (NPs-HGF-2 μg), 4 μg HGF (NPs-HGF-4 μg), and drug-free nanoparticles (NPs) using the W/O/W emulsion-solvent evaporation method in accordance with our patent. The morphology and physical characteristics were analyzed, and effects of HGF-loaded PLGA nanoparticles on a CCl4-induced acute liver injury mouse model were investigated and compared with HGF solutions. We observed that the morphology and the physical characteristics of the nanoparticles were almost the same, with similar sizes, polydispersity, and zeta potential. HGF-loaded PLGA nanoparticles maintained higher HGF concentrations for a longer period of time in blood and liver tissues. HGF-loaded PLGA nanoparticles increased the SOD activity and GPX levels, decreased the MDA levels in the liver, reduced the necrotic areas of the liver, and decreased the levels of AST, ALT, ALP, T-BIL, BUN, and Scr in blood. In conclusion, our technique for preparing HGF-loaded PLGA nanoparticles was stable and the products were of good quality. HGF-loaded PLGA nanoparticles could provide greater therapeutic benefits on CCl4-induced acute liver injury, including antilipid peroxidation and a reduction in indicator enzymes of liver injury.

show abstract

Comparative study on the effect of low intensity laser and growth factors on stem cells used in experimentally-induced liver fibrosis in mice

Cited by 5 publications

References 57 publications

Strategies to improve the efficiency of mesenchymal stem cell transplantation for reversal of liver fibrosis

Strategies to improve the efficiency of mesenchymal stem cell transplantation for reversal of liver fibrosis

Photobiomodulation Therapy to Mitigate Radiation Fibrosis Syndrome

Characterization and Evaluation of HGF-Loaded PLGA Nanoparticles in a CCl₄-Induced Acute Liver Injury Mouse Model

Contact Info

Product

Resources

About

Comparative study on the effect of low intensity laser and growth factors on stem cells used in experimentally-induced liver fibrosis in mice

Cited by 5 publications

References 57 publications

Strategies to improve the efficiency of mesenchymal stem cell transplantation for reversal of liver fibrosis

Strategies to improve the efficiency of mesenchymal stem cell transplantation for reversal of liver fibrosis

Photobiomodulation Therapy to Mitigate Radiation Fibrosis Syndrome

Characterization and Evaluation of HGF-Loaded PLGA Nanoparticles in a CCl4-Induced Acute Liver Injury Mouse Model

Contact Info

Product

Resources

About

Characterization and Evaluation of HGF-Loaded PLGA Nanoparticles in a CCl₄-Induced Acute Liver Injury Mouse Model